Non-neutralizing antibodies and limitations of serologic testing for severe acute respiratory syndrome coronavirus 2 in patients receiving immunoglobulin replacement products

Ann Allergy Asthma Immunol. 2021 Feb;126(2):206-207. doi: 10.1016/j.anai.2020.11.009. Epub 2020 Nov 21.

Authors

Deepti Vellaichamy Manian¹, Chelsee Jensen², Elitza S Theel³, John R Mills³, Avni Joshi⁴

Affiliations

¹ Division of Allergic Diseases, Department of Medicine, Mayo Clinic, Rochester, Minnesota.
² Mayo Clinic, Rochester, Minnesota.
³ Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota.
⁴ Division of Allergic Diseases, Department of Medicine, Mayo Clinic, Rochester, Minnesota. Electronic address: Joshi.avni@mayo.edu.

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Antibodies, Viral / blood*
COVID-19 / pathology
COVID-19 Serological Testing / methods*
Common Variable Immunodeficiency / immunology*
Enzyme-Linked Immunosorbent Assay
Female
Humans
Immunoglobulin G / therapeutic use*
Middle Aged
SARS-CoV-2 / immunology*
Serologic Tests

Substances

Antibodies, Viral
Immunoglobulin G